Measuring C5a with functional bioassay Dr. Michael Schwenkert and Ali Qamar
|
The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement systemAgnieszka Belter1, Anna-Maria Barciszewska2, and Miroslawa Naskręt-Barciszewska1
|
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.Pedro Miguel Coelho Medeiros1,2, Leon Cyranka1,3, Anne Rosbjerg3, Camilla Schjalm1, Peter Garred2,3, Reinhard Würzner2, and Tom Eirik Mollnes1,4,5
|
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterizationSandra Wymann1, Marcel Mischnik3, David Leong2, Subhajit Ghosh3, Xiahui Tan2, Helen Cao2, Benjamin Kuehnemuth3, Glenn Powers2, Partho Halder3, Mitchell de Souza2, Hannah James2, Vesna Tomasetig2, Holger Lind3, Paolo Rossato3, Catherine Owczarek2, Saw Yen Ow2, Steven Dower2, Adriana Baz Morelli2, Tony Rowe2, and Matthew Hardy2
|
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood modelBeatrice Fageräng1, Corinna Lau2, Pedro Coelho Medeiros1, Karin Mc Adam1, Camilla Schjalm1, Per Nilsson1,3, Peter Garred4, and Tom Eirik Mollnes1,2,5
|
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3Linnea Lindelöf1, David Eikrem1, Kristina Nilsson Ekdahl1,2, Peter Garred3, Bo Nilsson1, and Oskar Eriksson1
|
A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseasesGerald Cox1, Chin Meng Khoo2, Charlene Song1, and Judith Wu1
|
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic developmentEllen Millman1, Daniel Mills2, Oksana Shkilnyk2, Dieudonne Sidi2, Michelle Elvington3, Tobin Cammett1, and Martin Schmidt3
|
Fragment-based drug design in the development of novel inhibitors against the initiating protease, C1r, of the classical pathway of complementDenise Rohlik
|
Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological TargetsElod Kortvely1, Antonello Caruso2, Jannik Vollmer3, Matthias Machacek3, and Robin Denhardt-Eriksson3
|
Role of pentraxin 3 and interaction with complement in immune defence against malaria Hang Zhong
|
Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samplesSarika Agarwal, Troy Gilliam, and Patrick Sexton
|
Complement implication in the acute kidney injury associated with rhabdomyolysisA Grunenwald, V Poillerat, M Revel, E Voilin, T Robe-Rybkine, I Boudhabhay, S Sacks, Florent Petitprez, L Gilardin, and LT Roumenina
|
